Cargando…

The Current State of FLT3 Inhibition in Acute Myeloid Leukemia – Pitfalls and Promises

Detalles Bibliográficos
Autores principales:	Minson, Katherine A, DeRyckere, Deborah, Graham, Douglas K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964994/ https://www.ncbi.nlm.nih.gov/pubmed/29806049 http://dx.doi.org/10.4172/2576-1471.1000166

Ejemplares similares

Targeting the TAM Receptors in Leukemia
por: Huey, Madeline G., et al.
Publicado: (2016)

Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia
por: Lee-Sherick, Alisa B., et al.
Publicado: (2015)

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor
por: Zhang, Weihe, et al.
Publicado: (2014)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
por: El Fakih, Riad, et al.
Publicado: (2018)

Potential targeting of FLT3 acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2020)

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
por: Tecik, Melisa, et al.
Publicado: (2022)

Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
por: Yan, Dan, et al.
Publicado: (2021)

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia
por: Li, Dan, et al.
Publicado: (2020)

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2013)

Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia
por: Sexauer, Amy N., et al.
Publicado: (2017)

Clinical use of FLT3 inhibitors in acute myeloid leukemia
por: Sutamtewagul, Grerk, et al.
Publicado: (2018)

FLT3 inhibitors: clinical potential in acute myeloid leukemia
por: Hospital, Marie-Anne, et al.
Publicado: (2017)

Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
por: Ge, Shuai-Shuai, et al.
Publicado: (2022)

Disrupting autophagy in FLT3-mutant acute myeloid leukemia
por: Grant, Steven
Publicado: (2022)

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia
por: Brandao, L N, et al.
Publicado: (2013)

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
por: Zhang, Weiguo, et al.
Publicado: (2022)

Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission
por: Christoph, Sandra, et al.
Publicado: (2013)

Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia
por: Gilbert, Julie R, et al.
Publicado: (2022)

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia
por: Lee-Sherick, A B, et al.
Publicado: (2013)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus
por: Migdall-Wilson, Justine, et al.
Publicado: (2012)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
por: Smart, Sherri K., et al.
Publicado: (2018)

Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia
por: Mumme, Hope, et al.
Publicado: (2023)

Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
por: Lopez‐Reyes, Rosa G., et al.
Publicado: (2020)

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
por: Mali, Raghuveer Singh, et al.
Publicado: (2020)

Erratum: Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia
por: Lee-Sherick, A B, et al.
Publicado: (2016)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
por: Eguchi, Motoki, et al.
Publicado: (2020)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
por: Daver, Naval, et al.
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia
por: Song, Moo-Kon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iarr8ehue1b51kgl0s281ltqkn